A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Izokibep (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms AFFIRM-35
- Sponsors Affibody
- 12 Sep 2023 Results published in the British Journal of Dermatology
- 01 Feb 2022 Status changed from active, no longer recruiting to completed.
- 09 Jul 2020 Planned End Date changed from 1 Mar 2020 to 20 Dec 2022.